Article

CLM296: a highly selective inhibitor targeting ALDH1A3-driven tumor growth and metastasis in breast cancer

2025-04-18

Abstract excerpt

<h4>ABSTRACT</h4> Aldehyde dehydrogenase 1A3 (ALDH1A3) increases tumor growth, metastasis, and chemoresistance in many solid tumors, including triple-negative breast cancer (TNBC), glioblastoma, melanoma, lung, and colon cancers, yet no clinically approved inhibitors exist. Here, we present CLM296, a novel and highly selective ALDH1A3 inhibitor designed to address this unmet need. CLM296 exhibits potent inhibitio...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a7ea4660-2227-5aff-8890-59c96c479503
DOI: 10.1101/2025.04.16.649105

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

CLM296: a highly selective inhibitor targeting ALDH1A3-driven tumor growth and metastasis in breast cancerDOI 10.1101/2025.04.16.649105Read

A Selective Competitive Inhibitor of Aldehyde Dehydrogenase 1A3 Hinders Cancer Cell Growth, Invasiveness and Stemness In VitroSemantic proximity Read

ALDH1A3 affects colon cancer in vitro proliferation and invasion depending on CXCR4 statusSemantic proximity Read

The Expanding Role of Cancer Stem Cell Marker ALDH1A3 in Cancer and BeyondSemantic proximity Read

The Significance of Aldehyde Dehydrogenase 1 in CancersSemantic proximity Read

Molecular Characterization and Clinical Relevance of ALDH2 in Human CancersSemantic proximity Read

ALDH1A1 in Cancers: Bidirectional Function, Drug Resistance, and Regulatory MechanismSemantic proximity Read

Structure-Based Optimization of a Novel Class of Aldehyde Dehydrogenase 1A (ALDH1A) Subfamily-Selective Inhibitors as Potential Adjuncts to Ovarian Cancer ChemotherapySemantic proximity Read

Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells.Semantic proximity Read

Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide <i>In Vivo</i>Semantic proximity Read

A First-in-human Phase I Study of TAS0728, an Oral Covalent Binding Inhibitor of HER2, in Patients With Advanced Solid Tumors With HER2 or HER3 Aberrations.Semantic proximity Read

Identification of DLK1, a Notch ligand, as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinomaSemantic proximity Read

Serine/Threonine Kinase 33 as a Novel Target of Bufalin in Treatment of Triple‐Negative Breast CancerSemantic proximity Read